Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Vaccines
|
February 15, 2018
Virus-Like-Vaccines against HIV
Anne-Marie C Andersson, Melanie Schwerdtfeger, Peter J Holst
Journal of Translational Medicine
|
May 26, 2019
Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
Melanie Schwerdtfeger, Anne-Marie Carola Andersson, Lasse Neukirch, et al.
Translational Oncology
|
May 29, 2021
Long non-coding RNAs in cancer stem cells
Melanie Schwerdtfeger, Vincenzo Desiderio, Sebastian Kobold, et al.
Current Hematologic Malignancy Reports
|
May 3, 2021
Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job
Melanie Schwerdtfeger, Mohamed-Reda Benmebarek, Stefan Endres, et al.
Journal of Pharmaceutical Sciences
|
May 18, 2026
Lyophilization of a viral vaccine: Strategies for surrogate use in analytical characterization of cake properties and considerations on virus infectivity
Andrea Arsiccio, Felix Reuter, Sabine Ulamec, et al.
Cancer Treatment Reviews
|
June 8, 2020
The role of autophagy in resistance to targeted therapies
Luigi Mele, Vitale Del Vecchio, Davide Liccardo, et al.
Cell Death & Disease
|
October 14, 2020
β<sub>2</sub>-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism
Luigi Mele, Vitale Del Vecchio, Francesco Marampon, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 12, 2022
MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
Carmela Ferri, Anna Di Biase, Marco Bocchetti, et al.
Leukemia
|
January 8, 2021
A modular and controllable T cell therapy platform for acute myeloid leukemia
Mohamed-Reda Benmebarek, Bruno L Cadilha, Monika Herrmann, et al.
Journal for Immunotherapy of Cancer
|
May 19, 2023
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
Florian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Vaccines
|
February 15, 2018
Virus-Like-Vaccines against HIV
Anne-Marie C Andersson, Melanie Schwerdtfeger, Peter J Holst
Journal of Translational Medicine
|
May 26, 2019
Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine
Melanie Schwerdtfeger, Anne-Marie Carola Andersson, Lasse Neukirch, et al.
Translational Oncology
|
May 29, 2021
Long non-coding RNAs in cancer stem cells
Melanie Schwerdtfeger, Vincenzo Desiderio, Sebastian Kobold, et al.
Current Hematologic Malignancy Reports
|
May 3, 2021
Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job
Melanie Schwerdtfeger, Mohamed-Reda Benmebarek, Stefan Endres, et al.
Journal of Pharmaceutical Sciences
|
May 18, 2026
Lyophilization of a viral vaccine: Strategies for surrogate use in analytical characterization of cake properties and considerations on virus infectivity
Andrea Arsiccio, Felix Reuter, Sabine Ulamec, et al.
Cancer Treatment Reviews
|
June 8, 2020
The role of autophagy in resistance to targeted therapies
Luigi Mele, Vitale Del Vecchio, Davide Liccardo, et al.
Cell Death & Disease
|
October 14, 2020
β<sub>2</sub>-AR blockade potentiates MEK1/2 inhibitor effect on HNSCC by regulating the Nrf2-mediated defense mechanism
Luigi Mele, Vitale Del Vecchio, Francesco Marampon, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
January 12, 2022
MiR-423-5p prevents MALAT1-mediated proliferation and metastasis in prostate cancer
Carmela Ferri, Anna Di Biase, Marco Bocchetti, et al.
Leukemia
|
January 8, 2021
A modular and controllable T cell therapy platform for acute myeloid leukemia
Mohamed-Reda Benmebarek, Bruno L Cadilha, Monika Herrmann, et al.
Journal for Immunotherapy of Cancer
|
May 19, 2023
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
Florian Märkl, Mohamed-Reda Benmebarek, Julius Keyl, et al.
Page
of 2